Aducanumab (Aduhelm) for Alzheimer ' s Disease

Date: July 12, 2021 Issue #:  1628Summary:  Aducanumab-avwa (Aduhelm– Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer ' s disease. The approval was based on the surrogate endpoint of reduction in amyloid beta plaques in the brain. The manufacturer is required to conduct an additional randomized controlled trial to establish that reducing amyloid beta plaques with aducanumab improves clinical outcomes in patients with Alzheimer ' s disease.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: aducanumab Aduhelm Alzheimer ' s disease Donepezil Galantamine Memantine Rivastigmine Source Type: research